Methyl 2-[5-methyl-2-(3-methylthiophen-2-yl)-1,3-oxazol-4-yl]acetate | 196809-83-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: Methyl 2-[5-methyl-2-(3-methylthiophen-2-yl)-1,3-oxazol-4-yl]acetate
• CAS: 196809-83-3
• 化学式: C₁₂H₁₃NO₃S
• 分子量: 251.306
• InChiKey: XFJXYRTYQZYMAU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  80.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  Methyl 2-[5-methyl-2-(3-methylthiophen-2-yl)-1,3-oxazol-4-yl]acetate 在 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 2-(5-methyl-2-(3-methylthiophen-2-yl)oxazol-4-yl)ethyl methanesulfonate
  参考文献：
  名称：

  Revisiting glitazars: Thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents

  摘要：

  In an effort to develop safe and efficacious compounds for the treatment of metabolic disorders, novel thiophene substituted oxazole containing alpha-alkoxy-phenylpropanoic acid derivatives are designed as highly potent PPAR alpha/gamma dual agonists. These compounds were found to be efficacious at picomolar concentrations. Lead compound 18d has emerged as very potent PPAR alpha/gamma dual agonist demonstrating potent antidiabetic and lipid lowering activity at a very low dose and did not exhibit any significant signs of toxicity in rodents. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.03.020
• 作为产物：
  描述：

  4,5-dimethyl-2-(3-methylthiophen-2-yl)oxazole 3-oxide 在 硫酸 、 水 、 三氯氧磷 作用下， 以 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 34.0h， 生成 Methyl 2-[5-methyl-2-(3-methylthiophen-2-yl)-1,3-oxazol-4-yl]acetate
  参考文献：
  名称：

  Revisiting glitazars: Thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents

  摘要：

  In an effort to develop safe and efficacious compounds for the treatment of metabolic disorders, novel thiophene substituted oxazole containing alpha-alkoxy-phenylpropanoic acid derivatives are designed as highly potent PPAR alpha/gamma dual agonists. These compounds were found to be efficacious at picomolar concentrations. Lead compound 18d has emerged as very potent PPAR alpha/gamma dual agonist demonstrating potent antidiabetic and lipid lowering activity at a very low dose and did not exhibit any significant signs of toxicity in rodents. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.03.020

文献信息

• [EN] SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA<br/>[FR] DERIVES D'ACIDE 4-HYDROXY-PHENYLALCANOIQUE SUBSTITUE POSSEDANT UNE ACTIVITE AGONISTE ENVERS PPAR-GAMMA
  申请人：GLAXO GROUP LIMITED

  公开号：WO1997031907A1

  公开（公告）日：1997-09-04

  (EN) A compound having formula (I), wherein A is selected from the group consisting of: (i) phenyl, wherein said phenyl is optionally substituted by one or more halogen atoms, C1-6alkyl, C1-3alkoxy, C1-3fluoroalkoxy, nitrile, or -NR7R8 where R7 and R8 are independently hydrogen or C1-3alkyl; (ii) a 5- or 6-membered heterocyclic group containing at least one heteroatom selected from oxygen, nitrogen and sulfur; and (iii) a fused bicyclic ring (a), wherein ring C represents a heterocyclic group as defined in point (ii) above, which bicyclic ring is attached to group B via a ring atom of ring C; B is selected from the group consisting of: (iv) C1-6alkylene; (v) -MC1-6alkylene or C1-6alkyleneMC1-6alkylene, wherein M is O, S, or -NR2 wherein R2 represents hydrogen or C1-3 alkyl; (vi) a 5- or 6-membered heterocyclic group containing at least one nitrogen heteroatom and optionally at least one further heteroatom selected from oxygen, nitrogen and sulfur and optionally substituted by C1-3 alkyl; and (vii) Het-C1-6alkylene, wherein Het represents a heterocyclic group as defined in point (vi) above; Alk represents C1-3alkylene; R1 represents hydrogen or C1-3alkyl; Z is selected from the group consisting of: (viii) -(C1-3alkylene) phenyl, which phenyl is optionally substituted by one or more halogen atoms; and (ix) -NR3R4, wherein R3 represents hydrogen or C1-3alkyl, and R4 represents -Y-(C=O)-T-R5, or -Y-(CH(OH))-T-R5.(FR) Cette invention concerne un composé correspondant à la formule (I) où A est choisi dans le groupe comprenant les éléments suivants: (i) un phényle éventuellement substitué par un ou plusieurs atomes halogènes, alkyle C1-6, alcoxy C1-3, fluoroalcoxy C1-3, nitrile ou -NR7R8, R7 et R8 représentant indépendamment hydrogène ou alkyle C1-3; (ii) un groupe hétérocyclique à 5 ou 6 branches contenant un ou plusieurs hétéroatomes choisis parmi oxygène, azote et soufre; et (iii) un anneau (a) bicyclique fusionné dans lequel l'anneau C représente un groupe hétérocyclique tel que défini dans le point (ii) susmentionné, cet anneau bicyclique étant attaché au groupe B par un des atomes de l'anneau C. B est choisi dans le groupe comprenant les éléments suivants: (iv) alcylène C1-6; (v) -MC1-6alcylène ou C1-6alcylèneMC1-6alcylène où M représente O, S ou NR2, R2 représentant hydrogène ou alkyle C1-3; (vi) un groupe hétérocyclique à 5 ou 6 branches contenant au moins un hétéroatome d'azote et, éventuellement, un ou plusieurs autres hétéroatomes choisis parmi oxygène, azote et soufre, ledit groupe étant éventuellement substitué par alkyle C1-3; et (vii) Het-C1-6alcylène où Het représente un groupe hétérocyclique tel que défini dans le point (vi) susmentionné. Alk représente alcylène C1-3, tandis que R1 représente hydrogène ou alkyle C1-3, et que Z est choisi dans le groupe comprenant les éléments suivants: (viii) -(C1-3alcylène)phényle, lequel phényle est éventuellement substitué par un ou plusieurs atomes halogènes; et enfin (ix) -NR3R4 où R3 représente hydrogène ou alkyle C1-3, et R4 représente -Y-(C=O)-T-R5 ou -Y-(CH(OH))-T-R5.

  化合物的化学式为(I)，其中A选自以下组中的一种：(i)苯基，其中所述苯基可以选用一个或多个卤素原子，C1-6烷基，C1-3烷氧基，C1-3氟烷氧基，腈或-NR7R8，其中R7和R8独立地表示氢或C1-3烷基；(ii)含有至少一个氧、氮或硫杂原子的5-或6-成员杂环基；以及(iii)融合的双环环(a)，其中环C代表上述(ii)中定义的杂环基，该双环环通过环C的一个环原子连接到基团B上；B选自以下组中的一种：(iv)C1-6烷基；(v)-MC1-6烷基或C1-6烷基MC1-6烷基，其中M为O、S或-NR2，而R2表示氢或C1-3烷基；(vi)含有至少一个氮杂原子的5-或6-成员杂环基，且可选地含有至少一个来自氧、氮或硫的进一步杂原子，并可选地被C1-3烷基取代；以及(vii)Het-C1-6烷基，其中Het代表上述(vi)中定义的杂环基；Alk表示C1-3烷基；R1表示氢或C1-3烷基；Z选自以下组中的一种：(viii) -(C1-3烷基)苯基，所述苯基可以选用一个或多个卤素原子；以及(ix) -NR3R4，其中R3表示氢或C1-3烷基，而R4表示-Y-(C=O)-T-R5或-Y-(CH(OH))-T-R5。
• SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA
  申请人：GLAXO GROUP LIMITED

  公开号：EP0888317A1

  公开（公告）日：1999-01-07
• US6294580B1
  申请人：——

  公开号：US6294580B1

  公开（公告）日：2001-09-25
• Revisiting glitazars: Thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents
  作者：Preeti Raval、Mukul Jain、Amitgiri Goswami、Sujay Basu、Archana Gite、Atul Godha、Harikishore Pingali、Saurin Raval、Suresh Giri、Dinesh Suthar、Maanan Shah、Pankaj Patel

  DOI：10.1016/j.bmcl.2011.03.020

  日期：2011.5

  In an effort to develop safe and efficacious compounds for the treatment of metabolic disorders, novel thiophene substituted oxazole containing alpha-alkoxy-phenylpropanoic acid derivatives are designed as highly potent PPAR alpha/gamma dual agonists. These compounds were found to be efficacious at picomolar concentrations. Lead compound 18d has emerged as very potent PPAR alpha/gamma dual agonist demonstrating potent antidiabetic and lipid lowering activity at a very low dose and did not exhibit any significant signs of toxicity in rodents. (C) 2011 Elsevier Ltd. All rights reserved.